Cargando…

Monalizumab: inhibiting the novel immune checkpoint NKG2A

The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Hall, Thorbald, André, Pascale, Horowitz, Amir, Ruan, Dan Fu, Borst, Linda, Zerbib, Robert, Narni-Mancinelli, Emilie, van der Burg, Sjoerd H., Vivier, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798508/ https://www.ncbi.nlm.nih.gov/pubmed/31623687 http://dx.doi.org/10.1186/s40425-019-0761-3

Ejemplares similares

NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division
por: Borst, Linda, et al.
Publicado: (2021)

Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
por: Yaqinuddin, Ahmed, et al.
Publicado: (2020)

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
por: André, Pascale, et al.
Publicado: (2018)

Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A monoclonal antibody over monalizumab for the treatment of cancer
por: Spinosa, Phillip, et al.
Publicado: (2021)

TEIPP peptides: exploration of unTAPped cancer antigens
por: Marijt, Koen A., et al.
Publicado: (2019)

Future Challenges in Cancer Resistance to Immunotherapy
por: van Elsas, Marit J., et al.
Publicado: (2020)

Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer
por: Medjouel Khlifi, Hakim, et al.
Publicado: (2022)

Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement
por: Marijt, Koen A., et al.
Publicado: (2021)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
por: Geurts, V.C.M., et al.
Publicado: (2023)

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy
por: Doorduijn, Elien M., et al.
Publicado: (2017)

Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
por: Fransen, Marieke F., et al.
Publicado: (2021)

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling
por: Marijt, Koen A., et al.
Publicado: (2019)

Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy
por: Sluijter, Marjolein, et al.
Publicado: (2014)

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma
por: Yazdi, Mehrdad Talebian, et al.
Publicado: (2015)

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy
por: van Elsas, Marit J, et al.
Publicado: (2023)

T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1(b) with TAP-Independent Peptides Are Semi-Invariant Lymphocytes
por: Doorduijn, Elien M., et al.
Publicado: (2018)

Editorial: Innate Lymphoid Cells in Cancer: Friends or Foes?
por: Jacquelot, Nicolas, et al.
Publicado: (2021)

Visualizing Early Splenic Memory CD8(+) T Cells Reactivation against Intracellular Bacteria in the Mouse
por: Bajénoff, Marc, et al.
Publicado: (2010)

NKG2A is a NK cell exhaustion checkpoint for HCV persistence
por: Zhang, Chao, et al.
Publicado: (2019)

Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
por: Crinier, Adeline, et al.
Publicado: (2020)

The nonpolymorphic MHC Qa-1(b) mediates CD8(+) T cell surveillance of antigen-processing defects
por: Oliveira, Cláudia C., et al.
Publicado: (2010)

The nonpolymorphic MHC Qa-1(b) mediates CD8(+) T cell surveillance of antigen-processing defects
por: Oliveira, Cláudia C., et al.
Publicado: (2010)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through CD94/NKG2A receptor engagement
por: Wang, Xiaoli, et al.
Publicado: (2018)

Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
por: van Elsas, Marit, et al.
Publicado: (2020)

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody
por: van Elsas, Marit J., et al.
Publicado: (2022)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Kaulfuss, Meike, et al.
Publicado: (2023)

Immunotherapy of Human Papilloma Virus Induced Disease
por: van der Burg, Sjoerd H
Publicado: (2012)

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment
por: Gezgin, Gülçin, et al.
Publicado: (2017)

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
por: Kaidun, Polina, et al.
Publicado: (2023)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Identification of non-mutated neoantigens presented by TAP-deficient tumors
por: Marijt, Koen A., et al.
Publicado: (2018)

NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy
por: Cazzetta, Valentina, et al.
Publicado: (2023)

New prospects on the NKG2D/NKG2DL system for oncology
por: Ullrich, Evelyn, et al.
Publicado: (2013)

Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
por: Ding, Hui, et al.
Publicado: (2018)

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021)

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19
por: Demaria, Olivier, et al.
Publicado: (2020)

Immune checkpoints on innate lymphoid cells
por: Chiossone, Laura, et al.
Publicado: (2017)

The Paradoxical Role of NKG2D in Cancer Immunity
por: Sheppard, Sam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_li81vvc02hi3hvcfrouvedupc1